Appointment of Joint Broker

RNS Number : 2296V
Venture Life Group PLC
20 July 2018
 

20 July 2018

 

Venture Life Group plc

(the "VLG or the "Company")

 

Appointment of Joint Broker

 

Venture Life Group plc (AIM: VLG), the international consumer self-care group focused on developing, manufacturing and commercialising products for the self-care market is pleased to announce the appointment, with immediate effect, of Cenkos Securities plc as joint broker, alongside its existing nominated adviser and joint broker Northland Capital Partners Limited and Turner Pope Investments Limited. 

 

Contacts

Venture Life Group PLC

+44 (0) 1344 742870

Jerry Randall, Chief Executive Officer


Adrian Crockett, Chief Financial Officer  




Northland Capital Partners Limited
(Nominated Adviser and Joint Broker)

+44 (0) 20 3861 6625

Matthew Johnson / Edward Hutton (Corporate Finance)


Vadim Alexandre (Corporate Broking)




Cenkos Securities PLC (Joint Broker)

+44 (0) 20 7397 8900

Camilla Hume / Mark Connelly (Corporate Finance)


Michael F Johnson / Russell Kerr (Sales)




Turner Pope Investments (TPI) Ltd (Joint Broker)

+44 (0) 20 3621 4120

James Pope / Ben Turner




Walbrook PR

+ 44 (0) 20 7933 8780

Anna Dunphy

venturelife@walbrookpr.com

+44 (0) 7876 741 001


 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product portfolio includes some key products such as the UltraDEX oral care products range, food supplements for lowering cholesterol and maintaining brain function, medical devices for women's intimate healthcare and haemorrhoids and dermo-cosmetics for addressing the signs of ageing.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Through its Development & Manufacturing business in Italy, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCVKLFFVDFEBBZ
UK 100